Gilead Sciences, Inc 8-K, filed Aug 14, 2025
Gilead Sciences, Inc. (GILD)
8-K
2025-08-14
For: 2025-08-10
View Original
Added on
April 11, 2026
About this 8-K
Gilead Sciences, Inc filed this 8-K on August 14, 2025, reporting on events of August 10, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 10, 2025
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices)
(Zip Code)
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 10, 2025, the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the “Company”), appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer of the Company, effective as of September 22, 2025 (the “Transition Date”).
Ms. Burkhart, age 46, has served as Group Vice President and Chief Accounting Officer of BioMarin Pharmaceutical Inc., a biotechnology company, since May 2022. Ms. Burkhart previously worked at Eli Lilly and Company, a pharmaceutical company, from August 2014 to April 2022, where she held various accounting and finance roles of increasing responsibility during her tenure. Ms. Burkhart started her career in public accounting in 2001 with Arthur Andersen and Deloitte before serving in accounting and finance roles with various other companies. Ms. Burkhart is a licensed certified public accountant and holds a B.S. in Accounting from Butler University.
Ms. Burkhart succeeds Diane E. Wilfong, who will step down as the Company’s interim Controller and principal accounting officer, effective as of the Transition Date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GILEAD SCIENCES, INC. | ||
| (Registrant) | ||
| /s/ DEBORAH H. TELMAN | ||
| Deborah H. Telman EVP, Corporate Affairs, General Counsel and Corporate Secretary | ||
Date: August 14, 2025